CompletedPhase 2NCT00423735
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Studying Gliosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Andrew Lassman, MDNRG Oncology
- Intervention
- Dasatinib(drug)
- Enrollment
- 64 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2018
Study locations (30)
- Mobile Infirmary Medical Center, Mobile, Alabama, United States
- Arizona Oncology Services Foundation, Scottsdale, Arizona, United States
- The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States
- Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States
- Mercy San Juan Medical Center, Carmichael, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Glendale Adventist Medical Center, Glendale, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States
- Sutter Medical Center Sacramento, Sacramento, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- Mercy General Hospital Radiation Oncology Center, Sacramento, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Radiation Therapy Oncology Group · NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00423735 on ClinicalTrials.govOther trials for Gliosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07134842A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.University College, London
- ENROLLING BY INVITATIONPHASE1NCT06896110Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaAndrew P. Groves
- RECRUITINGPHASE1NCT06934889Study of ABBV-637 or ABBV-155 With ERAS-801 for People With GlioblastomaMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT05756985Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain TissueBaptist Health South Florida
- RECRUITINGPHASE2NCT05864534Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaNorthwestern University
- RECRUITINGNCT06954636Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational StudySied Kebir
- RECRUITINGPHASE1NCT04991870Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBMM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT05363826Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®Photolitec LLC